Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade

Journal of Thoracic Oncology

Volumn 12, Issue 8, 2017, Pages 1268-1279

  Akbay, Esra A ^a,b   Koyama, Shohei ^c   Liu, Yan ^d,e   Dries, Ruben ^d,e   Bufe, Lauren E ^e   Silkes, Michael ^e   Alam, MD Maksudul ^a,b   Magee, Dillon M ^a,b   Jones, Robert ^e   Jinushi, Masahisa ^f   Kulkarni, Meghana ^e   Carretero, Julian ^g   Wang, Xiaoen ^d,e   Warner Hatten, Tiquella ^e   Cavanaugh, Jillian D ^e   Osa, Akio ^c   Kumanogoh, Atsushi ^c   Freeman, Gordon J ^d,e   Awad, Mark M ^d,e   Christiani, David C ^h   Bueno, Raphael ⁱ   Hammerman, Peter S ^d,e   Dranoff, Glenn ^j   Wong, Kwok Kin ^k   more..

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d HARVARD MEDICAL SCHOOL   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f KEIO UNIVERSITY   (Japan)

^g UNIVERSITY OF VALENCIA   (Spain)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^k NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Cytokines; IL 17; MDSC; Neutrophils; PD 1; Resistance

Indexed keywords

CXCL1 CHEMOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 17; INTERLEUKIN 6; LACTADHERIN; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN P21;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GENE EXPRESSION; LUNG CANCER; MOUSE; NEUTROPHIL CHEMOTAXIS; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL ANALYSIS; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DISEASE EXACERBATION; GENETICS; HUMAN; IMMUNOLOGY; LUNG TUMOR; MUTATION; NEUTROPHIL; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; DISEASE PROGRESSION; GENE EXPRESSION; HUMANS; INTERLEUKIN-17; LUNG NEOPLASMS; MICE; MICE, TRANSGENIC; MUTATION; NEUTROPHILS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 85020135367     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2017.04.017     Document Type: Article

References (58)

1. Cancer Genome Atlas Research Network, Collisson, E.A., Campbell, J.D., et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511 (2014), 543–550.
2. de Mello, R.A., Madureira, P., Carvalho, L.S., Araújo, A., O'Brien, M., Popat, S., EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer. Pharmacogenomics 14 (2013), 1765–1777.
3. Rekhtman, N., Ang, D.C., Riely, G.J., Ladanyi, M., Moreira, A.L., KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. Mod Pathol 26 (2013), 1307–1319.
4. Meng, D., Yuan, M., Li, X., et al. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. Lung Cancer 81 (2013), 1–10.
5. Guan, J.L., Zhong, W.Z., An, S.J., et al. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy. Ann Surg Oncol 20 (2013), 1381–1388.
6. Takahashi, H., Ogata, H., Nishigaki, R., Broide, D.H., Karin, M., Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell 17 (2010), 89–97.
7. Ji, H., Houghton, A.M., Mariani, T.J., et al. K-ras activation generates an inflammatory response in lung tumors. Oncogene 25 (2006), 2105–2112.
8. Meylan, E., Dooley, A.L., Feldser, D.M., et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 462 (2009), 104–107.
9. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
10. Liao, C., Yu, Z., Guo, W., et al. Prognostic value of circulating inflammatory factors in non-small cell lung cancer: a systematic review and meta-analysis. Cancer Biomark 14 (2014), 469–481.
11. Jafri, S.H., Shi, R., Mills, G., Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer, 13, 2013, 158.
12. Tomita, M., Shimizu, T., Ayabe, T., Nakamura, K., Onitsuka, T., Elevated preoperative inflammatory markers based on neutrophil-to-lymphocyte ratio and C-reactive protein predict poor survival in resected non-small cell lung cancer. Anticancer Res 32 (2012), 3535–3538.
13. Iwakura, Y., Ishigame, H., Saijo, S., Nakae, S., Functional specialization of interleukin-17 family members. Immunity 34 (2011), 149–162.
14. Lotti, F., Jarrar, A.M., Pai, R.K., et al. Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med 210 (2013), 2851–2872.
15. Ma, S., Cheng, Q., Cai, Y., et al. IL-17A produced by gammadelta T cells promotes tumor growth in hepatocellular carcinoma. Cancer Res 74 (2014), 1969–1982.
16. Wang, K., Kim, M.K., Di Caro, G., et al. Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity 41 (2014), 1052–1063.
17. Coffelt, S.B., Kersten, K., Doornebal, C.W., et al. IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522 (2015), 345–348.
18. Li, L., Huang, L., Vergis, A.L., et al. IL-17 produced by neutrophils regulates IFN-gamma-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. J Clin Invest 120 (2010), 331–342.
19. Colotta, F., Allavena, P., Sica, A., Garlanda, C., Mantovani, A., Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30 (2009), 1073–1081.
20. Benchetrit, F., Ciree, A., Vives, V., et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 99 (2002), 2114–2121.
21. Chen, X., Wan, J., Liu, J., et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 69 (2010), 348–354.
22. Xu, C., Hao, K., Yu, L., Zhang, X., Serum interleukin-17 as a diagnostic and prognostic marker for non-small cell lung cancer. Biomarkers 19 (2014), 287–290.
23. Chang, S.H., Mirabolfathinejad, S.G., Katta, H., et al. T helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci U S A 111 (2014), 5664–5669.
24. Ji, W., Choi, C.M., Rho, J.K., et al. Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer. BMC Cancer, 13, 2013, 606.
25. Rothschild, S.I., Ceritinib-a second-generation ALK inhibitor overcoming resistance in ALK-rearranged non-small cell lung cancer. Transl Lung Cancer Res 3 (2014), 379–381.
26. Garon, E.B., Rizvi, N.A., Hui, R., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
27. Patel, S.P., Kurzrock, R., PD-L1 Expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14 (2015), 847–856.
28. Rizvi, N.A., Hellmann, M.D., Snyder, A., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
29. Herbst, R.S., Soria, J.C., Kowanetz, M., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
30. Ji, H., Li, D., Chen, L., et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9 (2006), 485–495.
31. Li, D., Shimamura, T., Ji, H., et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 12 (2007), 81–93.
32. DuPage, M., Dooley, A.L., Jacks, T., Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4 (2009), 1064–1072.
33. Jackson, E.L., Willis, N., Mercer, K., et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15 (2001), 3243–3248.
34. Fisher, G.H., Wellen, S.L., Klimstra, D., et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15 (2001), 3249–3262.
35. Chen, Z., Sasaki, T., Tan, X., et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res 70 (2010), 9827–9836.
36. Beard, C., Hochedlinger, K., Plath, K., Wutz, A., Jaenisch, R., Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. Genesis 44 (2006), 23–28.
37. Barber, D.L., Wherry, E.J., Masopust, D., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439 (2006), 682–687.
38. Akbay, E.A., Pena, C.G., Ruder, D., et al. Cooperation between p53 and the telomere-protecting shelterin component Pot1a in endometrial carcinogenesis. Oncogene 32 (2013), 2211–2219.
39. Koyama, S., Akbay, E.A., Li, Y.Y., et al. STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T cell activity in the lung tumor microenvironment. Cancer Res, 2016.
40. Akbay, E.A., Koyama, S., Carretero, J., et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 3 (2013), 1355–1363.
41. Miller, D.P., Liu, G., De Vivo, I., et al. Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk. Cancer Res 62 (2002), 2819–2823.
42. Koyama, S., Akbay, E.A., Li, Y.Y., et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun, 7, 2016, 10501.
43. Tchaicha, J.H., Akbay, E.A., Altabef, A., et al. Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC. Cancer Res 74 (2014), 4676–4684.
44. Miossec, P., Kolls, J.K., Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 11 (2012), 763–776.
45. Fridlender, Z.G., Albelda, S.M., Tumor-associated neutrophils: friend or foe?. Carcinogenesis 33 (2012), 949–955.
46. Fielding, C.A., McLoughlin, R.M., McLeod, L., et al. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J Immunol 181 (2008), 2189–2195.
47. Ancrile, B., Lim, K.H., Counter, C.M., Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 21 (2007), 1714–1719.
48. Takahashi, Y., Kawamura, M., Hato, T., Harada, M., Matsutani, N., Horio, H., Neutrophil-lymphocyte ratio as a prognostic marker for lung adenocarcinoma after complete resection. World J Surg 40 (2016), 365–372.
49. Li, Q., Han, Y., Fei, G., Guo, Z., Ren, T., Liu, Z., IL-17 promoted metastasis of non-small-cell lung cancer cells. Immunol Lett 148 (2012), 144–150.
50. Jackson, E.L., Olive, K.P., Tuveson, D.A., et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 65 (2005), 10280–10288.
51. Dougan, M., Li, D., Neuberg, D., et al. A dual role for the immune response in a mouse model of inflammation-associated lung cancer. J Clin Invest 121 (2011), 2436–2446.
52. Tumeh, P.C., Harview, C.L., Yearley, J.H., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
53. Chung, A.S., Wu, X., Zhuang, G., et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med 19 (2013), 1114–1123.
54. Yao, Z., Fenoglio, S., Gao, D.C., et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A 107 (2010), 15535–15540.
55. Lee, H.J., Zhuang, G., Cao, Y., Du, P., Kim, H.J., Settleman, J., Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 26 (2014), 207–221.
56. Taylor, P.R., Roy, S., Leal, S.M. Jr., et al. Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, RORgammat and dectin-2. Nat Immunol 15 (2014), 143–151.
57. Peng, D., Kryczek, I., Nagarsheth, N., et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527 (2015), 249–253.
58. Housseau, F., Wu, S., Wick, E.C., et al. Redundant innate and adaptive sources of IL-17 production drive colon tumorigenesis. Cancer Res 76 (2016), 2115–2124.